CN112876503B - Borate compound for cancer boron neutron capture therapeutic medicine and preparation thereof - Google Patents
Borate compound for cancer boron neutron capture therapeutic medicine and preparation thereof Download PDFInfo
- Publication number
- CN112876503B CN112876503B CN202110289828.3A CN202110289828A CN112876503B CN 112876503 B CN112876503 B CN 112876503B CN 202110289828 A CN202110289828 A CN 202110289828A CN 112876503 B CN112876503 B CN 112876503B
- Authority
- CN
- China
- Prior art keywords
- reaction
- borate compound
- compound
- sodium
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 Borate compound Chemical class 0.000 title claims abstract description 83
- 229910052796 boron Inorganic materials 0.000 title claims abstract description 33
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 title claims abstract description 32
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 201000011510 cancer Diseases 0.000 title claims abstract description 19
- 230000001225 therapeutic effect Effects 0.000 title claims description 7
- 238000002360 preparation method Methods 0.000 title abstract description 31
- 239000003814 drug Substances 0.000 title description 21
- 238000006243 chemical reaction Methods 0.000 claims description 97
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 42
- 239000007787 solid Substances 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 24
- 238000001816 cooling Methods 0.000 claims description 23
- 238000001914 filtration Methods 0.000 claims description 23
- 239000004327 boric acid Substances 0.000 claims description 17
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 15
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 12
- AKQNYQDSIDKVJZ-UHFFFAOYSA-N triphenylsilane Chemical compound C1=CC=CC=C1[SiH](C=1C=CC=CC=1)C1=CC=CC=C1 AKQNYQDSIDKVJZ-UHFFFAOYSA-N 0.000 claims description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000007810 chemical reaction solvent Substances 0.000 claims description 8
- 239000003381 stabilizer Substances 0.000 claims description 7
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- WWLVEMOKDAVHDW-UHFFFAOYSA-N C(CO)O.[Na].[Na] Chemical compound C(CO)O.[Na].[Na] WWLVEMOKDAVHDW-UHFFFAOYSA-N 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 3
- UCXUKTLCVSGCNR-UHFFFAOYSA-N diethylsilane Chemical compound CC[SiH2]CC UCXUKTLCVSGCNR-UHFFFAOYSA-N 0.000 claims description 3
- VDCSGNNYCFPWFK-UHFFFAOYSA-N diphenylsilane Chemical compound C=1C=CC=CC=1[SiH2]C1=CC=CC=C1 VDCSGNNYCFPWFK-UHFFFAOYSA-N 0.000 claims description 3
- NEXSMEBSBIABKL-UHFFFAOYSA-N hexamethyldisilane Chemical compound C[Si](C)(C)[Si](C)(C)C NEXSMEBSBIABKL-UHFFFAOYSA-N 0.000 claims description 3
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 claims description 3
- AMCPECLBZPXAPB-UHFFFAOYSA-N propane-1,2,3-triol;sodium Chemical compound [Na].OCC(O)CO AMCPECLBZPXAPB-UHFFFAOYSA-N 0.000 claims description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 claims description 3
- 159000000000 sodium salts Chemical class 0.000 claims description 3
- 230000000087 stabilizing effect Effects 0.000 claims description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- WVMSIBFANXCZKT-UHFFFAOYSA-N triethyl(hydroxy)silane Chemical compound CC[Si](O)(CC)CC WVMSIBFANXCZKT-UHFFFAOYSA-N 0.000 claims description 3
- AAPLIUHOKVUFCC-UHFFFAOYSA-N trimethylsilanol Chemical compound C[Si](C)(C)O AAPLIUHOKVUFCC-UHFFFAOYSA-N 0.000 claims description 3
- ZMHATUZXFSOVSC-UHFFFAOYSA-N triphenyl(triphenylsilyl)silane Chemical compound C1=CC=CC=C1[Si]([Si](C=1C=CC=CC=1)(C=1C=CC=CC=1)C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 ZMHATUZXFSOVSC-UHFFFAOYSA-N 0.000 claims description 3
- 239000008096 xylene Substances 0.000 claims description 3
- XBHPFCIWRHJDCP-UHFFFAOYSA-N (2-trimethylsilylphenyl) trifluoromethanesulfonate Chemical compound C[Si](C)(C)C1=CC=CC=C1OS(=O)(=O)C(F)(F)F XBHPFCIWRHJDCP-UHFFFAOYSA-N 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 abstract description 8
- 201000010536 head and neck cancer Diseases 0.000 abstract description 5
- 208000014829 head and neck neoplasm Diseases 0.000 abstract description 5
- 229940126585 therapeutic drug Drugs 0.000 abstract description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 abstract description 3
- 239000002253 acid Substances 0.000 abstract description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 3
- 229910052710 silicon Inorganic materials 0.000 abstract description 3
- 239000010703 silicon Substances 0.000 abstract description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 24
- 239000000047 product Substances 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 18
- 238000005160 1H NMR spectroscopy Methods 0.000 description 18
- 239000007795 chemical reaction product Substances 0.000 description 18
- 239000011521 glass Substances 0.000 description 18
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 14
- 239000002585 base Substances 0.000 description 14
- 230000008569 process Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 239000012298 atmosphere Substances 0.000 description 8
- RTXDMWNDEUYXPG-UHFFFAOYSA-N sodium;oxido(triphenyl)silane Chemical compound [Na+].C=1C=CC=CC=1[Si](C=1C=CC=CC=1)([O-])C1=CC=CC=C1 RTXDMWNDEUYXPG-UHFFFAOYSA-N 0.000 description 8
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- NFIVJOSXJDORSP-QMMMGPOBSA-N (2s)-2-amino-3-(4-boronophenyl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(B(O)O)C=C1 NFIVJOSXJDORSP-QMMMGPOBSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- 229940126062 Compound A Drugs 0.000 description 3
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 150000001642 boronic acid derivatives Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 108010059712 Pronase Proteins 0.000 description 2
- YAWNFGAHEUCLNJ-UHFFFAOYSA-N [B].OB(O)O Chemical compound [B].OB(O)O YAWNFGAHEUCLNJ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000006575 electron-withdrawing group Chemical group 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 125000004469 siloxy group Chemical group [SiH3]O* 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- GOXICVKOZJFRMB-UHFFFAOYSA-N (3-phenylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=2C=CC=CC=2)=C1 GOXICVKOZJFRMB-UHFFFAOYSA-N 0.000 description 1
- OBQRODBYVNIZJU-UHFFFAOYSA-N (4-acetylphenyl)boronic acid Chemical compound CC(=O)C1=CC=C(B(O)O)C=C1 OBQRODBYVNIZJU-UHFFFAOYSA-N 0.000 description 1
- UGZUUTHZEATQAM-UHFFFAOYSA-N (4-butylphenyl)boronic acid Chemical compound CCCCC1=CC=C(B(O)O)C=C1 UGZUUTHZEATQAM-UHFFFAOYSA-N 0.000 description 1
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 1
- SJGGDZCTGBKBCK-UHFFFAOYSA-N 3-acetylphenylboronic acid Chemical compound CC(=O)C1=CC=CC(B(O)O)=C1 SJGGDZCTGBKBCK-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-BJUDXGSMSA-N Boron-10 Chemical compound [10B] ZOXJGFHDIHLPTG-BJUDXGSMSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- PKWBMOXZIMVOJT-UHFFFAOYSA-N anthracen-2-ylboronic acid Chemical compound C1=CC=CC2=CC3=CC(B(O)O)=CC=C3C=C21 PKWBMOXZIMVOJT-UHFFFAOYSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical class B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- HUMMCEUVDBVXTQ-UHFFFAOYSA-N naphthalen-1-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=CC2=C1 HUMMCEUVDBVXTQ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0834—Compounds having one or more O-Si linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
The invention relates to a borate compound for a boron neutron capture therapeutic drug for cancer, which has the following structural general formula:(ii) a In the formula R1Is aryl, R2,R3,R4Are one of H, alkyl, aryl, silicon base and boron base. The invention also discloses a preparation method of the borate compound. The invention has better stability and acid resistance, and has stronger selectivity to head and neck cancer cells (CAL 27).
Description
Technical Field
The invention relates to the fields of medicinal chemistry and radiation medicine, in particular to a borate compound for a boron neutron capture therapeutic drug for cancer and a preparation method thereof.
Background
Head and neck cancer is a cancer with high incidence rate, great treatment difficulty and high mortality rate, and the eradication of the cancer is a great challenge in human medicine. In recent years, with the progress of drug development at home and abroad, people have made great progress in the development of anticancer drugs, but there is still a great need for new and more effective cancer treatment methods.
Boron Neutron Capture Therapy (BNCT) is a novel radiotherapy technology for targeting tumor cells, and BNCT is a binary method based on nuclear capture and fission reaction, and has the advantages of obvious low side effect, high selectivity and high efficiency compared with the traditional radiotherapy and chemotherapy. When non-radioactive is irradiated with low-energy thermal/epithermal neutrons10B atom, high Linear Energy Transfer (LET) alpha particle and7li recoils the nucleus. The high LET particles have a travel of 5-9 μm, close to a cell diameter, and are selective and contain only10The tumor cells of the B molecule generate strong heat action, and can kill cancer cells without causing excessive damage to surrounding normal cells.
At present, mercaptododecaborane disodium salt (BSH) and (L) -4-dihydroxyborylphenylalanine (BPA) have been clinically used for BNCT boron drugs for treating tumors [ patent publication nos. CN 111971563 a and CN 111204736 a ]; among them, BPA was approved and marketed in japan in 3 months of 2020, becoming the first BNCT boron drug approved and marketed worldwide. However, BSH and BPA are found to have the problem of insufficient tumor targeting in BNCT clinical research. Chemical structure modification of boronic acids and boranes is currently the main research strategy, but efficiency needs to be further improved. Patent application No. 201980041340.X proposes that an aggregating boron 10 agent can be used in boron neutron capture therapy, can selectively or locally target tumor tissues in a short time, and has the advantages of small side effect, low invasiveness and capability of exerting a local killing effect on the tumor tissues. Chinese patent 202011268512.8 discloses carborane-based celecoxib, a preparation method thereof and application thereof in boron neutron capture treatment medicines for head and neck cancer. Chinese patent 202010020070.9 discloses a preparation method of boron-containing carbon quantum dots and application thereof in medicines for tumor diagnosis and boron neutron capture therapy, wherein the boron-containing carbon quantum dots have good biocompatibility and excellent in-vivo fluorescence imaging effect.
The microenvironment of the tumor cells is weakly acidic (pH = 6.5-6.8), while the lysosomes of the tumor cells are more acidic (pH around 5.0). If the alkalinity of the boron-containing molecules is increased, the selectivity of the boron drug in cancer cells is expected to be further improved. The four-coordination boric acid compound has certain alkalescence, is a common intermediate in the chemical reaction of organic boric acid molecules, and has very limited research on the compound due to higher instability. In 2020, Lijihui et al reported that arylboronic acid compounds can be effectively stabilized in the presence of silane and that arylboronic acid sodium salt can be used as a catalyst in heterogeneously catalyzed reactionsGreen Chem., 2020, 22, 5317-5324]. Therefore, on the basis of improving the stability of borate, the boric acid boron drug molecules are modified to obtain the boron neutron capture treatment drug for cancer with higher efficiency.
Disclosure of Invention
The invention aims to provide a borate compound which has better stability and acid resistance and is used for boron neutron capture therapeutic drugs for cancers.
The invention also provides a preparation method of the borate compound for the boron neutron capture treatment medicine for the cancer.
In order to solve the above problems, the borate compound for boron neutron capture therapeutic drugs for cancer according to the present invention is characterized in that: the structural general formula of the borate compound is as follows:
(ii) a In the formula R1Is aryl, R2 , R3 , R4Are one of H, alkyl, aryl, silicon base and boron base.
The preparation method of the borate compound for the boron neutron capture therapeutic medicine for cancer is characterized by comprising the following steps: adding a boric acid compound, strong base and a reaction solvent into a reaction container, reacting at 25-180 ℃ for 30 s-48 h, and cooling to room temperature to obtain a reaction solution A; filtering the reaction solution A to obtain a solid A, and recrystallizing and separating the solid A to obtain a borate compound A; the molar ratio of the boronic acid compound to the strong base is 1: 0.5-1: 10.
the chemical reaction formula is as follows (formula I):
the preparation method of the borate compound for the boron neutron capture therapeutic medicine for cancer is characterized by comprising the following steps: adding a boric acid compound, strong base and a reaction solvent into a reaction container, reacting at 25-180 ℃ for 30 s-48 h, adding a stabilizing reagent, and cooling to room temperature after the reaction is finished to obtain a reaction solution B; filtering the reaction solution B to obtain a solid B, and recrystallizing and separating the solid B to obtain a borate compound B; the molar ratio of the boronic acid compound to the strong base is 1: 0.5-1: 10; the molar ratio of the boronic acid compound to the stabilizing agent is 1: 0.5 to 5.
The chemical reaction formula is as follows (formula II):
the boric acid compound refers to aryl boric acid or aliphatic boric acid.
The boric acid compound is that a benzene ring is connected with B (OH)2Of phenylalanine group, ofStructural formula is(ii) a In the formula R1It means that various functional groups in phenyl, p-tolyl, methyl, trifluoromethyl, chain or cyclic alkyl, aryl comprising fused rings or heterocycles, siloxy and halogen are mono-substituted or multi-substituted.
The structural formula of the boric acid compound is one of the following formulas:
the strong base refers to a hydroxide or alkoxylate of a metal.
The strong base is one of NaOH, KOH, LiOH, sodium methoxide, sodium ethoxide, ethylene glycol disodium, sodium glycerol and sodium salt of sugar.
The stabilizing agent is any agent with an electron withdrawing group.
The stabilizing agent is one of reagents of sodium pentafluorophenyl, phenylsilane, diphenylsilane, triphenylsilane, 2- (trimethyl silicon) phenyl trifluoromethanesulfonic acid, hexamethyldisilane, hexaphenyldisilane, tert-butyldimethylchlorosilane, diethylsilane, triethylsilane, trimethylsilanol and triethylsilanol.
The reaction solvent refers to an organic solvent, including but not limited to one or more of dimethyl sulfoxide, N-dimethylformamide, tetrahydrofuran, acetonitrile, methanol, dioxane, N-methylpyrrolidone, toluene, xylene and mesitylene.
The reaction temperature is preferably 60-100 ℃; the reaction time is preferably 1-6 h.
Compared with the prior art, the invention has the following advantages:
1. compared with the prior research object limited to boric acid compounds, the invention discloses a preparation method of four-coordination borate based on a stabilization strategy, and the obtained borate has better stability and acid resistance, and breaks through the conventional understanding that the borate is unstable and easy to decompose.
2. According to the invention, the charge of borate anions is dispersed by utilizing metal with certain Lewis acidity, Si group, B group and other groups, so that the improvement of borate stability is effectively realized.
3. The invention is a brand new improvement to the scope of the known BNCT boron medicament, successfully enriches and expands the scope of the boron medicament, fills the defects of the existing borate preparation technology, and realizes the high-efficiency and low-cost production of various borates with different structures.
4. The borate biological activity test result provided by the invention shows that the borate derived from BPA has stronger selectivity on head and neck cancer cells (CAL27), has obvious apoptosis induction effect on the head and neck cancer cells in boron neutron capture treatment, and shows better efficiency than BPA, thereby being expected to reduce the dosage of boron drugs, and showing better application prospect compared with the traditional boric acid boron drugs.
5. The invention has simple process and high synthesis efficiency.
Detailed Description
A borate compound for a boron neutron capture therapeutic agent for cancer, the borate compound having the general structural formula:
(ii) a In the formula R1Is aryl, R2 , R3 , R4Are one of H, alkyl, aryl, silicon base and boron base.
The materials used in the following examples are commercially available unless otherwise specified.
[ one-step method ]
The preparation method of the borate compound used for the boron neutron capture therapeutic medicine of the cancer comprises the following steps:
adding a boric acid compound, strong base and a reaction solvent into a reaction container, reacting at 25-180 ℃ for 30 s-48 h, and cooling to room temperature to obtain a reaction solution A; and filtering the reaction solution A to obtain a solid A, and recrystallizing and separating the solid A to obtain the borate compound A.
[ two-step Process ]
The preparation method of the borate compound used for the boron neutron capture therapeutic medicine of the cancer comprises the following steps:
adding a boric acid compound, strong base and a reaction solvent into a reaction container, reacting at 25-180 ℃ for 30 s-48 h, adding a stabilizing reagent, and cooling to room temperature after the reaction is finished to obtain a reaction solution B; and filtering the reaction solution B to obtain a solid B, and recrystallizing and separating the solid B to obtain the borate compound B.
Wherein: the boric acid compound refers to an arylboronic acid or an aliphatic boronic acid. Such as: 4-dihydroxyborylphenylalanine (BPA), phenylboronic acid, 1-naphthylboronic acid, 2-anthracenylboronic acid, methylboronic acid, 3-acetylphenylboronic acid, 3-biphenylboronic acid, 4-n-butylbenzeneboronic acid, 4-acetylphenylboronic acid and the like.
The boric acid compound is that a benzene ring is connected with B (OH)2The structural formula of the radical phenylalanine compound is(ii) a In the formula R1It means that various functional groups in phenyl, p-tolyl, methyl, trifluoromethyl, chain or cyclic alkyl, aryl comprising fused rings or heterocycles, siloxy and halogen are mono-substituted or multi-substituted.
The structural formula of the boric acid compound is one of the following:
strong bases refer to hydroxides or alkoxylates of metals.
The strong base is one of NaOH, KOH, LiOH, sodium methoxide, sodium ethoxide, ethylene glycol disodium, sodium glycerol and sodium salt of sugar.
Stabilizing agent refers to any agent with an electron withdrawing group.
The stabilizing agent is one of reagents of sodium pentafluorophenyl, phenylsilane, diphenylsilane, triphenylsilane, 2- (trimethylsilyl) phenyltrifluoromethanesulfonic acid, hexamethyldisilane, hexaphenyldisilane, tert-butyldimethylchlorosilane, diethylsilane, triethylsilane, trimethylsilanol and triethylsilanol.
The reaction solvent refers to an organic solvent, including but not limited to one or more of dimethyl sulfoxide, N-dimethylformamide, tetrahydrofuran, acetonitrile, methanol, dioxane, N-methylpyrrolidone, toluene, xylene, and mesitylene.
The reaction temperature is preferably 60-100 ℃; the reaction time is preferably 1-6 h.
The strong alkali is a pure product prepared in advance or purchased directly from a commercial channel; the boric acid compound can be prepared in advance and used after separation and purification, and can also be prepared in situ in the reaction process and directly used without any treatment.
The borate compound A and the borate compound B are four-coordinate borate, the chemical structural formulas of which are shown in formulas I and II, and the preferred structures are as follows:
example 1: preparation of borate compound (1) (two-step process).
(L) -4-Dihydroboranophenylalanine (0.05 mmol, 10.45 mg), sodium hydroxide (0.15 mmol, 6 mg), toluene (4 mL), and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. Triphenylsilane (0.15 mmol, 39 mg) was then added, and the reaction tube was reacted at 90 ℃ for 6 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 78%.
1H NMR (300 MHz, DMSO) δ 12.89 (s, 1H), 8.71 (d, 2H), 7.75 (d, 2H), 7.46 (m, 18H), 7.39-7.35 (m, 27H), 7.2(d, 2H), 4.18(s, 1H), 3.42(d, 2H).
13C NMR (100 MHz, DMSO) δ 174.7, 138.3, 136.6, 135.7, 133.3, 132.5,130.0, 129.5, 127.7, 56.7, 37.3.
EXAMPLE 2 preparation of Borate Compound (2) (one-step method)
Phenylboronic acid (0.05 mmol, 6.1 mg), sodium triphenylsilanolate (0.025 mmol, 7.46 mg), and a magnetic stir bar were added to a 35 mL glass pressure tube under air. Toluene (4 mL) was then added and the reaction tube was allowed to react at 90 ℃ for 6 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 75%.
1H NMR (300 MHz, DMSO) δ 7.75(d, 2H), 7.48 - 7.44 (m, 6H),7.37-7.39(m, 10m) 7.36(s, 1H), 7.35(s, 1H), 4.2 (d, 2H).
13C NMR (101 MHz, DMSO) δ 138.5, 138.3, 133.4, 132.5, 130.0, 129.5, 128.7.
EXAMPLE 3 preparation of Borate Compound (3) (two-step Process)
Phenylboronic acid (0.05 mmol, 6.1 mg), sodium hydroxide (0.5 mmol, 20 mg), toluene (4 mL) and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. Triphenylsilane (0.15 mmol, 39 mg) was then added, and the reaction tube was reacted at 90 ℃ for 12 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 75%.
1H NMR (300 MHz, DMSO) δ 7.75 (d, 2H), 7.48- 7.44 (m, 18H), 7.34 - 7.38 (m, 30H).
13C NMR (101 MHz, DMSO) δ 138.3, 133.4, 132.5, 130.0, 129.5, 128.7.
EXAMPLE 4 preparation of Borate Compound (4) (one-step method)
F-BPA (0.05 mmol, 11.35 mg), sodium triphenylsilanolate (0.2 mmol, 59.68 mg), and a magnetic stir bar were added to a 35 mL glass pressure tube under air. The reaction tube was reacted at 90 ℃ for 6 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 85%.
1H NMR (300 MHz, DMSO) δ 12.89 (s, 1H), 8.71 (d, 2H), 7.52 (s, 1H), 7.46 (m, 6H), 7.35-7.39 (m, 9H), 7.18 (s, 1H), 7.04 (s, 1H), 4.2(d, 2H), 4.18 (m, 1H), 3.42 (d, 2H).
13C NMR (101 MHz, DMSO) δ 174.7, 160.2, 138.3, 137.3, 132.5, 130.0, 129.5, 128.1, 115.6, 56.7, 32.4.
EXAMPLE 5 preparation of Borate Compound (5) (two-step Process)
BPA-Tyr (0.05 mmol, 18.61 mg), potassium hydroxide (0.2 mmol, 11.2 mg), toluene (4 mL), and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. Triphenylsilane (0.25 mmol, 65.10 mg) was then added, and the reaction tube was reacted at 100 ℃ for 10 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 70%.
1H NMR (300 MHz, DMSO) δ 12.8 9 (m, 1H), 9.06 (m, 1H), 8.86 (m, 2H), 8.32 (m, 1H), 7.75 (d, 2H), 7.48-7.44 (m, 24H), 7.38-7.34 (m, 20), 7.2 (m, 2H), 6.96 (m, 2H), 6.68 (m, 2H), 4.72 (m, 1H), 3.95 (d, 1H), 3.44 (m, 2H), 3.12 (m, 2H).
13C NMR (101 MHz, DMSO) δ 174.7, 171.7, 155.7, 138.3, 136.6, 135.7, 132.5, 130.2, 130.0, 129.5, 129.2,127.7, 115.8, 59.2, 56.0, 38.7, 36.5.
EXAMPLE 6 preparation of Borate Compound (6) (one-shot method)
BPA-Tyr (0.05 mmol, 18.61 mg), sodium triphenylsilanolate (0.05 mmol, 14.92 mg), and a magnetic stir bar were added to a 35 mL glass pressure tube under air. Toluene (10 mL) was then added and the reaction tube was allowed to react at 90 ℃ for 6 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 85%.
1H NMR (300 MHz, DMSO) δ 12.89 (s, 1H), 9.06 (s, 1H), 8.86 (m, 2H), 8.32 (s, 1H), 7.75 (m, 2H) 7.46(m, 6H), 7.38-7.34 (m, 9H), 7.20 (m, 2H), 6.96 (m, 2H), 6.68 (m, 2H), 4.72 (m, 1H), 4.20 (m, 2H), 3.95 (m, 1H), 3.44 (m, 2H), 3.21 (m, 2H).
13C NMR (101 MHz, DMSO) δ 174.7, 171.7, 155.7, 138.3,136.6, 135.7, 133.3, 132.5, 130.2, 130.0, 129.5, 129.2, 127.7, 115.8, 59.2, 56.0, 38.7, 36.5.
Example 7 preparation of Borate Compound (7) (two-step Process)
(L) -4-Dihydroxyborylphenylalanine (0.05 mmol, 10.45 mg), potassium hydroxide (0.2 mmol, 11.2 mg), toluene (4 mL), and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. Triphenylsilane (0.025 mmol, 6.51 mg) was then added and the reaction tube was reacted at 100 ℃ for 10 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 75%.
1H NMR (500 MHz, Chloroform-d) δ 7.64–7.57 (m, 7H), 7.61–7.53 (m, 1H), 7.39–7.29 (m, 9H), 7.12 (dt, J = 9.5, 1.1 Hz, 1H), 3.05–2.91 (m, 1H).
13C NMR (125 MHz, Chloroform-d) δ 174.88, 139.48, 135.07, 134.68, 133.60, 133.39, 132.18, 129.80, 127.46, 56.92, 37.79.
EXAMPLE 8 preparation of Borate Compound (8) (one-shot method)
BPA-Tyr (0.05 mmol, 18.61 mg), sodium triphenylsiloxide (0.2 mmol, 59.68 mg), a magnetic stir bar was added to a 35 mL glass pressure tube under air. Toluene (4 mL) was then added and the reaction tube was allowed to react at 80 ℃ for 48 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 78%.
1H NMR (500 MHz, Chloroform-d) δ 7.90 (d, J = 9.0 Hz, 1H), 7.64-7.57 (m, 7H), 7.59-7.52 (m, 2H), 7.39-7.29 (m, 10H), 7.14 (dt, J = 9.1, 1.1 Hz, 2H), 6.95 (dt, J = 8.6, 1.1 Hz, 2H), 6.75-6.69 (m, 2H), 6.14 (s, 1H), 5.92 (s, 2H), 4.54 (dt, J = 9.0, 6.8 Hz, 1H), 3.88 (p, J = 5.9 Hz, 1H), 3.02 (m, J = 15.4, 5.7, 1.0 Hz, 1H), 2.95 (m, J = 6.8, 2.7, 1.0 Hz, 2H), 2.88 (m, J = 15.2, 5.7, 1.0 Hz, 1H), 2.58 (dd, J = 8.0, 6.0 Hz, 1H), 2.42 (dd, J = 8.0, 5.9 Hz, 1H).
13C NMR (125 MHz, Chloroform-d) δ 176.68, 173.61, 156.46, 136.89, 135.07, 134.96, 134.52, 132.75, 130.65, 129.99, 129.80, 128.56, 127.46, 115.72, 54.89, 54.55, 38.40, 37.66.
Example 9 preparation of Borate Compound (9) (two-step Process)
Tyr-BPA (0.05 mmol, 18.61 mg), sodium hydroxide (0.2 mmol, 8 mg), toluene (4 mL) and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. Triphenylsilane (0.15 mmol, 39 mg) was then added, and the reaction tube was reacted at 90 ℃ for 12 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 90%.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.57 (m, 7H), 7.61-7.53 (m, 1H), 7.39-7.29 (m, 11H), 7.07 (m, J = 19.2, 8.6, 1.1 Hz, 2H), 6.75-6.69 (m, 1H), 4.54 (dt, J = 9.0, 6.8 Hz, 0H), 3.06-2.96 (m, 1H).
13C NMR (125 MHz, Chloroform-d) δ 176.69, 173.61, 156.84, 139.48, 135.16, 135.07, 133.60, 133.11, 132.17, 130.70, 129.80, 127.46, 127.25, 115.38, 54.88, 54.55, 38.39, 37.19.
EXAMPLE 10 preparation of Borate Compound (10) (one-shot method)
(L) -4-Dihydroboranophenylalanine (0.05 mmol, 10.45 mg), sodium triphenylsilanolate (0.05 mmol, 14.92 mg) and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. DCE (4 mL) was then added and the reaction tube allowed to react at 80 ℃ for 24 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 89%.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.57 (m, 3H), 7.61-7.52 (m, 1H), 7.39-7.29 (m, 4H), 7.13 (dt, J = 9.0, 1.0 Hz, 1H), 5.92 (s, 1H), 3.87 (tt, J = 6.6, 5.1 Hz, 0H), 3.05-2.91 (m, 1H).
13C NMR (125 MHz, Chloroform-d) δ 174.88, 136.89, 135.07, 134.96, 134.63, 132.84, 129.99, 129.80, 127.46, 56.92, 37.79.
EXAMPLE 11 preparation of Borate Compound (11) (two-step Process)
(L) -4-Dihydroboranophenylalanine (0.05 mmol, 10.45 mg), lithium hydroxide (0.15 mmol, 3.6 mg), DMF (4 mL) and a magnetic stirrer were added to a 35 mL glass pressure tube under air. Triphenylsilane (0.15 mmol, 39 mg) was then added, and the reaction tube was reacted at 90 ℃ for 12 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 72%.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.57 (m, 7H), 7.61-7.53 (m, 1H), 7.39-7.29 (m, 9H), 7.12 (dt, J = 9.5, 1.1 Hz, 1H), 3.05-2.91 (m, 1H).
13C NMR (125 MHz, Chloroform-d) δ 174.88, 139.48, 135.07, 134.68, 133.60, 133.39, 132.18, 129.80, 127.46, 56.92, 37.79.
EXAMPLE 12 preparation of Borate Compound (12) (one-shot method)
Tyr-BPA (0.05 mmol, 18.61 mg), sodium triphenylsilanolate (0.1 mmol, 29.84 mg) and a magnetic stir bar were added to a 35 mL glass pressure tube under air. Toluene (4 mL) was then added and the reaction tube was allowed to react at 90 ℃ for 12 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 90%.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.56 (m, 18H), 7.47-7.41 (m, 2H), 7.37-7.27 (m, 27H), 7.10-7.01 (m, 4H), 6.73-6.67 (m, 2H), 4.38 (dt, J = 9.1, 6.8 Hz, 1H), 3.84 (p, J = 5.9 Hz, 1H), 3.08-3.00 (m, 1H), 3.04-2.95 (m, 2H), 2.84 (m, J = 15.4, 5.8, 1.1 Hz, 1H), 2.70 (dd, J = 7.9, 6.0 Hz, 1H), 2.50 (dd, J = 8.0, 5.9 Hz, 1H).
13C NMR (125 MHz, Chloroform-d) δ 176.69, 173.61, 156.84, 139.48, 135.16, 135.07, 133.60, 133.11, 132.17, 130.70, 129.80, 127.46, 127.25, 115.38, 54.88, 54.55, 38.39, 37.19.
Example 13 preparation of Borate Compound (13) (two-step Process)
F-BPA (0.05 mmol, 11.35 mg), sodium hydroxide (0.2 mmol, 8 mg), toluene (4 mL) and a magnetic stir bar were added to a 35 mL glass pressure tube under air. Triphenylsilane (0.15 mmol, 39 mg) was then added, and the reaction tube was reacted at 80 ℃ for 24 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure product yield of the target product is 55 percent.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.56 (m, 8H), 7.43 (dd, J = 10.5, 2.0 Hz, 0H), 7.39-7.23 (m, 10H), 3.89 (tt, J = 7.5, 6.6 Hz, 0H), 3.18-3.07 (m, 1H).
13C NMR (125 MHz, Chloroform-d) δ 173.42, 135.07, 133.63, 129.80, 127.46, 32.61, 32.57.
EXAMPLE 14 preparation of Borate Compound (14) (one-shot method)
Tyr-BPA (0.05 mmol, 18.61 mg), sodium triphenylsilanolate (0.2 mmol, 59.68 mg) and a magnetic stir bar were added to a 35 mL glass pressure tube under air. 1, 2-dichloroethane (4 mL) was then added and the reaction tube was allowed to react at 90 ℃ for 12 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 85%.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.55 (m, 18H), 7.59-7.53 (m, 2H), 7.39-7.29 (m, 28H), 7.07 (m, J = 19.2, 8.6, 1.1 Hz, 4H), 6.75-6.69 (m, 2H), 4.53 (dt, J = 9.0, 6.7 Hz, 1H), 3.88 (p, J = 5.9 Hz, 1H), 3.06-2.98 (m, 1H), 3.00 (d, J = 1.1 Hz, 1H), 3.01-2.96 (m, 1H), 2.89 (m, J = 15.4, 5.7, 1.1 Hz, 1H), 2.58 (dd, J = 8.0, 6.0 Hz, 1H), 2.42 (dd, J = 8.0, 5.9 Hz, 1H).
13C NMR (125 MHz, Chloroform-d) δ 176.69, 173.61, 156.84, 139.48, 135.16, 135.07, 133.60, 133.11, 132.17, 130.70, 129.80, 127.46, 127.25, 115.38, 54.88, 54.55, 38.39, 37.19.
EXAMPLE 15 preparation of Borate Compound (15) (two-step Process)
F-BPA derivative (0.05 mmol, 11.35 mg), sodium hydroxide (0.2 mmol, 8 mg), toluene (4 mL) and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. Triphenylsilane (0.15 mmol, 39 mg) was then added, and the reaction tube was reacted at 90 ℃ for 12 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 88%.
1H NMR (500 MHz, Chloroform-d) δ 7.61 (dq, J = 8.4, 2.4, 1.9 Hz, 26H), 7.39-7.27 (m, 34H), 4.59 (dt, J = 6.2, 3.7 Hz, 1H), 4.18-4.08 (m, 2H), 4.03-3.91 (m, 2H), 3.93-3.84 (m, 1H), 3.18-3.07 (m, 2H).
13C NMR (125 MHz, Chloroform-d) δ 174.56, 161.90, 136.15, 136.08, 135.54, 135.09, 133.91, 133.72, 133.38, 133.36, 132.29, 131.42, 129.88, 128.87, 127.42, 127.40, 122.21, 120.65, 104.54, 77.48, 76.42, 72.57, 64.44, 61.18, 54.64, 30.56.
EXAMPLE 16 preparation of Borate Compound (16) (one-shot method)
Tyr-BPA (0.05 mmol, 18.61 mg), sodium triphenylsilanolate (0.2 mmol, 59.68 mg) and a magnetic stir bar were added to a 35 mL glass pressure tube under air. N, N-dimethylformamide (4 mL) was then added, and the reaction tube was reacted at 100 ℃ for 3 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 81%.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.55 (m, 18H), 7.59-7.53 (m, 2H), 7.39-7.29 (m, 28H), 7.07 (m, J = 19.2, 8.6, 1.1 Hz, 4H), 6.75-6.69 (m, 2H), 4.53 (dt, J = 9.0, 6.7 Hz, 1H), 3.88 (p, J = 5.9 Hz, 1H), 3.06-2.98 (m, 1H), 3.00 (d, J = 1.1 Hz, 1H), 3.01-2.96 (m, 1H), 2.89 (m, J = 15.4, 5.7, 1.1 Hz, 1H), 2.58 (dd, J = 8.0, 6.0 Hz, 1H), 2.42 (dd, J = 8.0, 5.9 Hz, 1H).
13C NMR (125 MHz, Chloroform-d) δ 176.69, 173.61, 156.84, 139.48, 135.16, 135.07, 133.60, 133.11, 132.17, 130.70, 129.80, 127.46, 127.25, 115.38, 54.88, 54.55, 38.39, 37.19.
EXAMPLE 17 preparation of Borate Compound (17) (two-step Process)
F-BPA derivative (0.05 mmol, 11.35 mg), lithium hydroxide (0.15 mmol, 3.6 mg), N, N-dimethylformamide (4 mL) and a magnetic stirrer were added to a 35 mL glass pressure tube under an air atmosphere. Triphenylsilane (0.15 mmol, 39 mg) was then added and the reaction tube was allowed to react at 80 ℃ for 24 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 80%.
1H NMR (500 MHz, Chloroform-d) δ 7.61 (m, J = 8.4, 2.4, 1.9 Hz, 26H), 7.39-7.27 (m, 34H), 4.59 (dt, J = 6.2, 3.7 Hz, 1H), 4.18-4.08 (m, 2H), 4.03-3.91 (m, 2H), 3.93-3.84 (m, 1H), 3.18-3.07 (m, 2H).
13C NMR (125 MHz, Chloroform-d) δ 174.56, 161.90, 136.15, 136.08, 135.54, 135.09, 133.91, 133.72, 133.38, 133.36, 132.29, 131.42, 129.88, 128.87, 127.42, 127.40, 122.21, 120.65, 104.54, 77.48, 76.42, 72.57, 64.44, 61.18, 54.64, 30.56.
EXAMPLE 18 preparation of Borate Compound (18) (one-shot method)
F-BPA derivative (0.05 mmol, 11.35 mg), sodium triphenylsilanolate (0.2 mmol, 59.68 mg) and a magnetic stir bar were added to a 35 mL glass pressure tube under air. 1, 2-dichloroethane (4 mL) was then added and the reaction tube was allowed to react at 90 ℃ for 12 hours. After the reaction is finished, cooling the reaction system to room temperature, opening the reaction container at room temperature, and filtering; and recrystallizing the obtained solid and separating to obtain a reaction product. The pure yield of the target product is 78%.
1H NMR (500 MHz, Chloroform-d) δ 7.64-7.56 (m, 6H), 7.44 (dd, J = 10.6, 1.8 Hz, 1H), 7.39-7.31 (m, 5H), 7.34-7.27 (m, 4H), 7.26 (s, 1H), 7.11 (m, J = 10.5, 5.0, 1.0 Hz, 1H), 4.59-4.52 (m, 2H), 4.49 (dd, J = 7.3, 6.6 Hz, 1H), 4.27 (dd, J = 7.3, 6.6 Hz, 1H), 4.15 (t, J = 6.2 Hz, 1H), 4.06 (s, 1H), 4.01-3.94 (m, 2H), 3.97-3.84 (m, 2H), 3.78-.68 (m, 2H), 3.46 (d, J = 5.1 Hz, 1H), 3.20-3.06 (m, 2H).
13C NMR (125 MHz, Chloroform-d) δ 173.42, 161.19, 159.18, 135.07, 133.94, 133.88, 133.67, 131.79, 131.72, 129.80, 128.72, 128.70, 127.46, 123.85, 123.69, 122.75, 122.59, 98.00, 78.45, 72.97, 72.74, 62.44, 60.93, 55.32, 55.30, 32.74, 32.70.
[ measurement of Borate uptake into CAL27 cells ]
CAL27 cells in logarithmic growth phase with 60-75% cell content were seeded into 6-well plates (1X 10 per well)6Individual cells). When the cells adhered, the cells were treated with BPA or borate compounds at concentrations of 20 or 100. mu.M, respectively, for 48 h (3 replicates per group and a blank control group). After the action is finished, removing the culture solution, and washing the cells for 3 times by using PBS; subsequently 1mL pronase solution with a concentration of 2mg/mL was added per well and incubated at 4 ℃ for 4 h. Discarding the pronase-containing solution, washing the cells 3 times with PBS, lysing the cells with RIPA lysate, collecting the cell lysate, centrifuging and collecting the supernatant. Detection in supernatant by ICP-MS10And (4) B concentration.
TABLE 1 measurement of the uptake of borate compounds in CAL27 cells
(should be compared to normal cell results)
As shown in Table 1, the uptake of the borate compound prepared by the invention in CAL27 cells is directly correlated with the acting concentration, and the uptake of the borate compound in CAL27 cells is higher than that of the positive control group BPA at the same concentration.
Claims (2)
2. the method of preparing a borate compound for use in a boron neutron capture therapy for cancer according to claim 1, wherein: adding a boric acid compound, strong base and a reaction solvent into a reaction container, reacting at 25-180 ℃ for 30 s-48 h, adding a stabilizing reagent, and cooling to room temperature after the reaction is finished to obtain a reaction solution B; filtering the reaction solution B to obtain a solid B, and recrystallizing and separating the solid B to obtain a borate compound B; the molar ratio of the boronic acid compound to the strong base is 1: 0.5-1: 10; the molar ratio of the boronic acid compound to the stabilizing agent is 1: 0.5 to 5;
the structural formula of the boric acid compound is one of the following formulas:
the strong base is one of NaOH, KOH, LiOH, sodium methoxide, sodium ethoxide, ethylene glycol disodium, sodium glycerol and sodium salt of sugar; the stabilizing agent is one of reagents of sodium pentafluorophenyl, phenylsilane, diphenylsilane, triphenylsilane, 2- (trimethylsilyl) phenyltrifluoromethanesulfonic acid, hexamethyldisilane, hexaphenyldisilane, tert-butyldimethylchlorosilane, diethylsilane, triethylsilane, trimethylsilanol and triethylsilanol; the reaction solvent includes, but is not limited to, one or more of dimethylsulfoxide, N-dimethylformamide, tetrahydrofuran, acetonitrile, methanol, dioxane, N-methylpyrrolidone, toluene, xylene, mesitylene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110289828.3A CN112876503B (en) | 2021-03-18 | 2021-03-18 | Borate compound for cancer boron neutron capture therapeutic medicine and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110289828.3A CN112876503B (en) | 2021-03-18 | 2021-03-18 | Borate compound for cancer boron neutron capture therapeutic medicine and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112876503A CN112876503A (en) | 2021-06-01 |
CN112876503B true CN112876503B (en) | 2022-04-29 |
Family
ID=76042692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110289828.3A Active CN112876503B (en) | 2021-03-18 | 2021-03-18 | Borate compound for cancer boron neutron capture therapeutic medicine and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112876503B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116410216B (en) * | 2023-04-12 | 2024-05-07 | 东莞市人民医院 | Small molecular boron medicine, preparation method thereof, pharmaceutical composition and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2740451B1 (en) * | 1995-10-27 | 1998-01-16 | Seripharm | NOVEL INTERMEDIATES FOR THE HEMISYNTHESIS OF TAXANES, THEIR PREPARATION METHODS AND THEIR USE IN THE GENERAL SYNTHESIS OF TAXANES |
UY29149A1 (en) * | 2004-10-07 | 2006-05-31 | Boehringer Ingelheim Int | TIAZOLIL-DIHIDRO-INDAZOLES |
JOP20190231A1 (en) * | 2009-01-15 | 2017-06-16 | Incyte Corp | Processes for preparing jak inhibitors and related intermediate compounds |
CN103848856B (en) * | 2012-11-30 | 2016-08-03 | 苏州汉德景曦新药研发有限公司 | There is the camptothecin derivative of anti-tumor activity |
-
2021
- 2021-03-18 CN CN202110289828.3A patent/CN112876503B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN112876503A (en) | 2021-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109970630B (en) | Two-photon fluorescent probe capable of targeting mitochondria and preparation method and application thereof | |
JP6831834B2 (en) | Method of preparing L-BPA | |
CN111039847B (en) | Magnolol derivative and preparation method and application thereof | |
CN112876503B (en) | Borate compound for cancer boron neutron capture therapeutic medicine and preparation thereof | |
CN102417491A (en) | Method for preparing cabazitaxel by taking 10-deacetylate-baccatin III as raw material | |
CN114560885B (en) | Sound-sensitive agent with low phototoxicity and preparation method and application thereof | |
CN110642878A (en) | Preparation method of fluorine-labeled BPA | |
JPWO2012018015A1 (en) | Cyclic ring-containing amino acid skeleton-bound boron compounds | |
ES2725498T3 (en) | Preparation of lithium phosphate catalysts | |
CN102442972A (en) | Industrial preparation method for pramipexole and its dihydrochloride monohydrate | |
CN108295882B (en) | Preparation of core-shell nano catalyst and application of core-shell nano catalyst in preparation of tinib drugs | |
CN108658733B (en) | Preparation method of 2,4, 6-triiodoresorcinol | |
CN108283940B (en) | Preparation method of palbociclib intermediate | |
CN107573336B (en) | Benzoheterocycle-formamide-pyridone derivative and preparation method and application thereof | |
CN104151339A (en) | Boron-containing acridine derivative as well as preparation method and application thereof | |
CN105348309A (en) | F-BPA nucleophilic synthesis method | |
CN101775029A (en) | Convenient synthesis method for alkyl substitution phenyloboricacid | |
CN111592560A (en) | Photosensitizer probe and preparation method and application thereof | |
CN110642879A (en) | Preparation method of fluorine-labeled BPA | |
CN114031786B (en) | Preparation method and application of metal organic framework for alkane C-H bond activation coupling reaction | |
CN116925112A (en) | Preparation method of key intermediate for boron neutron capture therapy | |
CN112574245A (en) | 4-10Preparation method of boric acid group-L-phenylalanine | |
CN103554116B (en) | A kind of molecular targeted anticancer photosensitizer tamoxifen-phthalocyanine conjugates and preparation method thereof | |
WO2023184731A1 (en) | Preparation method for 4- 10 boric acid-l-phenylalanine intermediate | |
CN114539303A (en) | Carborane-containing benzylguanidine compound and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |